Akeso’s ivonescimab obtains NDA priority review from China NMPA
The recent priority review procedure will help validate the clinical significance of the PD-1/VEGF bi-specific antibody and will…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Aug 23
The recent priority review procedure will help validate the clinical significance of the PD-1/VEGF bi-specific antibody and will…
28 Aug 23
Two implants were successfully conducted as part of the FDA approved Early Feasibility Study in the United States
25 Aug 23
In an interim analysis, cabozantinib significantly prolonged the time without disease progression or death in both cohorts of…
25 Aug 23
The approval was based on a strong data package that included functional, analytical and clinical data which showed…
25 Aug 23
No cases of shingles (herpes zoster) reported among the participants who received Shingrix (Recombinant Zoster Vaccine or RZV)…
25 Aug 23
This Approval Supports Veklury’s Strong Safety Profile and Makes Veklury the Only Approved COVID-19 Antiviral Treatment Across all…
24 Aug 23
With ODD, NXC-201 is now eligible for seven years of US market exclusivity in the US upon regulatory…
24 Aug 23
Funding from Wellcome will further broaden Vaxxas’ diverse clinical pipeline of next-generation vaccines to include Typhoid fever
23 Aug 23
The approval was based on the findings from the Phase 3 CheckMate -76K trial in which Opdivo lowered…
23 Aug 23
The American biotechnology company is now submitting applications for its XBB.1.5 Covid vaccine candidate to regulatory agencies all…